Indiplon Driving Study Could Push Marketing Into High Gear
Pfizer/Neurocrine's insomnia drug – which just had its user fee date extended – would still have class warnings, but could enjoy a labeling advantage over competitors.
Pfizer/Neurocrine's insomnia drug – which just had its user fee date extended – would still have class warnings, but could enjoy a labeling advantage over competitors.